A 43-year-old man is diagnosed with chronic myeloid leukemia (CML) and started on standard imatinib therapy (tyrosine kinase inhibitor, TKI). Which of the following clinical findings indicate this therapy protocol is NOT appropriate and should be altered? O Ph+ chromosome is undetectable in bone marrow cells after 9 months of treatment. O The BCR ABL1 (fusion) to ABL1 (wild-type) expression (MRNA) ratio is significantly reduced after 3 months of treatment. O The expression (MRNA) ratio of BCR-ABL1/ABL1 is down to 0.08% after 18 months of therapy. O 1-month into therapy and the patient shows an increased frequency of bone marrow cells with the Ph+ chromosome. O His WBC counts have returned to normal levels.

A 43-year-old man is diagnosed with chronic myeloid leukemia (CML) and started on standard imatinib therapy (tyrosine kinase inhibitor, TKI). Which of the following clinical findings indicate this therapy protocol is NOT appropriate and should be altered? O Ph+ chromosome is undetectable in bone marrow cells after 9 months of treatment. O The BCR ABL1 (fusion) to ABL1 (wild-type) expression (MRNA) ratio is significantly reduced after 3 months of treatment. O The expression (MRNA) ratio of BCR-ABL1/ABL1 is down to 0.08% after 18 months of therapy. O 1-month into therapy and the patient shows an increased frequency of bone marrow cells with the Ph+ chromosome. O His WBC counts have returned to normal levels.

Biology Today and Tomorrow without Physiology (MindTap Course List)

5th Edition

ISBN:9781305117396

Author:Cecie Starr, Christine Evers, Lisa Starr

Publisher:Cecie Starr, Christine Evers, Lisa Starr

Chapter10: Biotechnology

Section: Chapter Questions

Problem 4DID

See similar textbooks

Similar questions

Wilms tumor 1, or nephroblastoma, is caused by mutations in the WT1 gene, which encodes a transcription factor. You have identified a novel variant in WT1: Arg422Pro. You have control cells and cells that have been engineered to carry the homozygous WT1 p.Arg422Pro mutation. You want to assess effects of this mutation on a variety of endpoints. For each endpoint listed below, choose the one technique is best suited to answer the question. Choose from: array CGH, qRT-PCR, qPCR, RNA-seq, FISH, in situ hybridization, western blot, immunostaining, WT1 ChIP-seq, WT1 ChIP-PCR, ATAC-seq, 3C Endpoint Technique? WT1 protein amount (quantitative) Western blot WT1 protein binding to all enhancers, genome-wide Chip-seq WT1 mRNA amount (quantitative) WT1 protein subcellular localization Quantitative assessment of all mRNAs in these cells (genome-wide) RNAseq Chromatin interactions between a specific WT1 chromatin binding site (identified above)…
High dose chemotherapy given prior to stem cell transplant may be associated with gonadal failure. Risk is least with the use of. Select one: OA Busulfan + cyclophosphamide OB. Cyclophosphamide + TBI OC. Ifosfamide +carboplatin+ Etoposide OD Fludarabine + ATG
A patient comes into your clinic exhibiting generic cancer symptoms. In order to help form a diagnosis, you ask about patient history and they tell you that they worked for years in an agricultural job, primarily in handling food for large bovine animals and then later working with insect pesticide treatment of grain fields. You decide to test for elevated levels of the environmental agent(s) in their body and focus your cancer diagnosis on based on the established associations of epigentic effects and cancer. O nickel and cadmium; stomach and skin cancer O benzene; breast, prostate and thyroid cancer O polycyclic aromatic hydrocarbons and benzene; lung, breast, stomach and skin cancer O arsenic and endocrine disruptors; skin, bladder, liver and kidney cancer
Name the mutation at the protein level which is the basis for mutant A-1 Would a nonsense mutation in protein A be an enhancer or suppressor mutation of mutant B-1 Name the mutation at the phenotype level when a new function is acquired: ____morphic
A/a O A"/a afa Q afa Q Unsupplemented Supplemented b A"/a offspring Unsupplemented mother Supplemented mother This question relates to the aqouti mice research discussed in the lecture. What did the researchers observe in the experimental group (AVYA x aa) that was fed diets high in methyl donors? They gained weight rapidly. Increased expression of aqouti gene. Reduced risk of chronic disease Higher percentage of yellow offspring.
Refer to the following illustration to answer the question. O protein A is not made because it is normally required for its own transcription TRANSIENT SIGNAL TURNS ON EXPRESSION OF PROTEIN A What is protein A? O a maintenance methyltransferase O a histone PAY O a cell type-specific gene regulator a HAT (histone acetyltransferase) any of the above PAD the effect of the transient signal is remembered in all of the cell's descendants
S-Cdk is likely to be a [Select] The inhibitor of Ras is likely to be a [Select] The MAP kinase is likely to be a [Select] Q Search 14:31 Protein X is a transcription factor that normally activates the expression of genes needed for S- phase. The activator of protein X is likely to be a [Select] is 4 ******* > 21**113 ***** ****** V f6 99+ 1- Il app.honorlock.com is sharing your screen. **** 1 a hp Stop sha
BCL2 binds to and inactivates BAX and other pro-apoptotic proteins, thereby inhibiting apoptosis. Venetoclax has been approved for marketing in patients with chronic lymphocytic leukemia (CLL) Venetoclax is a highly selective BCL2 inhibitor that disrupts the interaction of this protein with BH3 domain proteins thereby permitting apoptosis. Proapoptotic Proapoptotic proteins protein binds to BCL2 BCL2 Venetoclax Venetoclax displaces proapoptotic proteins BCL2 Venetoclax Proapoptotic proteins No venetoclax binding BCL2 Glys01Val mutation Which of the following can you conclude from this information? Select all that apply Bcl2- mutations that prevent Ventoclax binding promote cell survival Venetoclax binding to Bcl2 promotes cell survival . Venetoclax binding to Bcl2 promotes cell death Proapoptotic protein binding to Bcl2 promotes cell survival
You are evaluating a patient with Nonpolyposis colorectal cancer and his biopsy pathology report reveals a defect in some TSGs involved in DNA mismatch repair, which of these genes is least likely to be implicated in this patients cancer? Group of answer choices SMAD4 MSH2 MLH1 PMS1
Name the mutation at the protein level which is the basis for mutant B-1 Would a nonsense mutation in protein A be an enhancer or suppressor mutation of mutant B-1 Name the mutation at the phenotype level when a new function is acquired: ____morphic Name one mutation which is a suppressor of bri1-5
The following statements may be either true or false. Please circle your answer. True / False RNAi-silencing occurs only in C. elegans but not in other organisms. True / False The same gene can be silenced by degradation of its mRNA in a parental animal, and by methylation of its DNA locus in the progeny. True / False Drosha and Pasha bind to mRNAs allowing the 43S subunit to form, but they inhibit the formation of the 80S subunit. True / False Injection of GFP-dsRNA into a C. elegans will activate the RISC complex and lead to the degradation of let-7 mRNA. True / False Nuclear GFP fluorescence was used in most experiments because RNAi- silencing occurs in the nucleus and not in the cytoplasm.
Following are the characteristics of organoids, except: Organoids are in vitro 3D clusters of cells deriving exclusively from primary tissue or stem cells Organoids are capable of self-renewal and self-organization. 2D monolayer cultures are much closer to the in vivo situation than the organoids Spatially restricted cell-fate decisions contribute to self-organization in organoids.